Clinical and Translational Neuroscience (Mar 2023)

Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Family Planning within the Management of MS

  • Mona M. Al-Khawajah,
  • Rayan G. Al-Barakati,
  • Ahmed H. Al-Jedai,
  • Yaser M. Al-Malik,
  • Hajer Y. Al-Mudaiheem,
  • Bedor A. Al-Omari,
  • Ibtisam A. Al-Thubaiti,
  • Rumaiza H. Al-Yafeai,
  • Reem F. Bunyan,
  • Edward J. Cupler,
  • Mohammed Hakami,
  • Hanaa M. Kedah,
  • Seraj Makkawi,
  • Leena H. Saeed,
  • Jameelah A. Saeedi,
  • Eslam Shosha,
  • Mohammed A. Al-Jumah

DOI
https://doi.org/10.3390/ctn7020010
Journal volume & issue
Vol. 7, no. 2
p. 10

Abstract

Read online

This review article addresses the complex issues faced by individuals with Multiple Sclerosis (MS) who are planning a family, becoming pregnant, or wishing to breastfeed their baby. Recommendations and guidelines were discussed and agreed upon by neurologists, neuroradiologists, nurses, and pharmacists involved in the management of MS in the Kingdom of Saudi Arabia (KSA). MS itself does not harm a pregnancy, and people with MS of childbearing age can be encouraged to enjoy family life. Family planning should be a part of the initial conversation with a newly diagnosed patient of childbearing age. Interferons and glatiramer acetate can be continued throughout pregnancy and can be administered during breastfeeding if the benefits outweigh the risks. These DMTs may be considered for a woman with well-controlled MS who is planning a pregnancy or otherwise not using contraception, according to an individualized risk-benefit analysis. The use of contraception should be maintained during the administration of other disease-modifying therapies (DMTs). Natalizumab can be administered at a reduced administration frequency to women with high MS disease activity up to 30 weeks gestation (this agent may induce hematological abnormalities in the fetus). Other DMTs should be withdrawn for variable periods before contraception is stopped and immediately after the discovery of a pregnancy (beware of rebound disease activity after withdrawing natalizumab or fingolimod). Resumption of treatment should not be delayed in women at risk of relapse during the postpartum period and especially in those who do not wish to breastfeed.

Keywords